Depo-Provera lawsuit update

Verified snapshot

The facts that anchor this dossier

A careful guide to the fast-growing federal Depo-Provera meningioma litigation: what the court is actually deciding, what the newest FDA label says, and why an epidemiologic association is not the same thing as proof in an individual case.

Federal proceeding

MDL 3140

Centralized in the Northern District of Florida before Judge M. Casey Rodgers.

Pending federal actions

5,830

JPML count as of July 1, 2026; this excludes state-court cases and is not a forecast of outcomes.

Historical actions

5,916

Total actions reported by JPML as filed in or transferred to the MDL through July 1, 2026.

Core alleged injury

Meningioma

Plaintiffs allege that repeated depot medroxyprogesterone acetate exposure caused one or more tumors; defendants dispute liability.

FDA label status

Meningioma warning added

The prescribing information revised in December 2025 says cases have been reported, primarily with long-term use, and directs monitoring and discontinuation if diagnosed.

Documented chronology

How the litigation reached this point

What this litigation is really about

Depo-Provera is the brand most people recognize, but the coordinated litigation is framed more broadly around depot medroxyprogesterone acetate, or DMPA. The JPML said the centralized actions share questions about whether the injectable contraceptive can cause meningioma, what manufacturers knew, whether warnings were adequate, and whether safer alternatives should have been promoted. Those are allegations and disputed questions, not findings that the drug caused every tumor reported by a plaintiff.

An MDL is a pretrial coordination device. It puts discovery, recurring legal motions, and expert-evidence disputes before one federal judge; it does not automatically turn thousands of individual suits into a class action or erase the facts unique to each person. Product identification, timing and duration of use, medical diagnosis, other risk factors, state law, and the proof linking an exposure to an injury can still matter case by case.

What the science shows—and what it does not

The 2024 French national case-control study is the evidence that accelerated public attention. Researchers compared 18,061 women who underwent intracranial meningioma surgery with 90,305 matched controls. Prolonged injectable medroxyprogesterone acetate exposure was associated with higher odds of surgery for meningioma. The result is important because of the study's size and national health-data design, but it remains observational: exposure measurement, confounding, selection of a surgical endpoint, and differences between populations all matter when translating a population-level association into an individual causal conclusion.

Later U.S. database studies also reported associations, including stronger estimates with longer exposure, while emphasizing that the absolute clinical risk was low. The MDL court, not a traffic-driven calculator, will decide what expert testimony is admissible under Federal Rule of Evidence 702. That process tests methodology and fit; it is different from a regulator changing a label and different again from proving specific causation for one patient.

The current FDA label is a crucial piece of context

The December 2025 FDA-approved prescribing information now contains a meningioma subsection. It says cases have been reported following repeated medroxyprogesterone acetate administration, primarily with long-term use, tells clinicians to monitor for signs and symptoms, and says to discontinue the product if a meningioma is diagnosed. That is meaningful safety information, but the wording does not say every user is likely to develop a tumor or that the medicine caused a particular person's diagnosis.

The label also retains a boxed warning about loss of bone mineral density and says long-term contraceptive use beyond two years is generally not recommended unless other methods are inadequate. Patients should not stop or switch prescribed contraception based on litigation advertising. A prescribing clinician can discuss the current label, a person's treatment history, warning symptoms, and medically appropriate alternatives without turning that conversation into a legal judgment.

Where the federal case stands

This is no longer merely an intake-stage docket. The court established pilot cases, required threshold proof of use and injury, coordinated with related state proceedings, oversaw general-causation expert discovery, and scheduled Rule 702 work. In March 2026 the court said member filings were rising rapidly, but the more reliable portfolio metric is the JPML's later July report: 5,830 actions pending out of 5,916 historical actions.

Pretrial Order 30A disclosed that leadership counsel and certain defendants had reached a global agreement and said only plaintiffs meeting criteria agreed by the parties would have an opportunity to resolve claims. The public order does not provide a universal payout chart, does not make every DMPA user a participant, and does not justify an online conclusion about anyone's status. The same order contemplated continuing expert-evidence work because not all cases would be resolved.

How to read future updates without being misled

Watch the court's orders on Rule 702 and preemption, not unsourced predictions. A Rule 702 ruling concerns whether particular expert opinions may be presented; preemption asks whether federal regulatory law forecloses some state-law warning claims. Either can reshape a docket without deciding every individual case. Also separate the federal MDL count from cases pending in Delaware, New York, California, or other state courts.

The most useful personal records are ordinary ones: pharmacy and insurer records, injection dates, product or manufacturer identification when available, imaging and pathology reports, and the clinical history surrounding a diagnosis. The court's threshold-proof order shows why records matter, but it is not a public checklist for legal qualification. Limitation periods and substantive rules differ by jurisdiction, so no generic webpage can responsibly calculate a deadline or outcome.

Reader questions

Frequently asked questions